P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium

Background:Vedolizumab (VDZ) is used to treat moderately-to-severely active Crohn's disease (CD) and ulcerative colitis (UC). Loss of response (LOR) to anti-TNF therapy at 12 months occurs in up to 46% of patients and can often be managed with dose intensification. Rates and risk factors for LOR to